SHOT Data. Why are SCT Patients a Special Group? Transfusion Problems in Stem Cell Transplant (SCT) Patients. BMT Patients are not a Special Group
|
|
- Cory Nash
- 5 years ago
- Views:
Transcription
1 Transfusion Problems in Stem Cell Transplant (SCT) Patients Derwood Pamphilon Clinical Director Stem Cells NHS Blood and Transplant Bristol, UK Why are SCT Patients a Special Group? Severely immunocompromised Highly prone to infections viral, bacterial, fungal Susceptible to Graft v Host Disease (GVHD) Change of blood groups BMT Patients are not a Special Group SHOT Data Total ICBT ATR DTR PTP TA-GVHD TRALI TTI Administration of wrong blood (ICBT) Acute/delayed transfusion reactions Alloimmunisation to HLA and subsequent platelet transfusion refractoriness Transmission of infection TA-GVHD Febrile reactions (FNHTR) TRALI Death Major Total
2 Regulations the EU Directive on Blood and Blood Components Regulations the EU Directive on Blood and Blood Components The EU Directive 2002/98/EC sets standards for the collection, testing, processing, storage and distribution of human blood and blood components The fate of each unit of all blood components should be recorded and this record kept for 30 years. i.e. vein-tovein traceability Robust Quality Systems should be in place It requires that Blood Establishments should be licensed and this is of importance for both Blood Centres in EU countries that undertake these activities as well as hospitals that collect and issue e.g. granulocytes for transfusion The processing of blood and blood components should be undertaken by licensed blood establishments Training should be provided for hospital transfusion laboratory staff Haemovigilance systems should be established to include the reporting of adverse events Components For Transfusion Platelet Transfusion Key Questions Red Cells - correction of anaemia Platelets - correction of thrombocytopenia/abnormal platelet function with bleeding Need to consider: Dose given Frequency Threshold for use What are the correct transfusion thresholds? Should prophylactic transfusions be given? Is there evidence to support current practice? FFP - management of bleeding with abnormal coagulation Co-administration of other products Granulocytes - prophylaxis/ therapy of infection Assessment of efficacy 2
3 Prospective RCTs of platelet transfusion Cochrane Systematic Review Platelet Transfusion Thresholds in SCT Zumberg et al 8 reports reviewed 3 older studies prophylactic v therapeutic 3 contemporary studies compared 10 v 20 thresholds. No differences in mortality, remission rates, severe bleeding, red cell transfusion requirements 3 investigated the effect of different platelet dose schedules insufficient data to make clinically relevant conclusions No reasons to change practice Consider adequately powered studies of prophylaxis v therapeutic transfusion Prospective RCT included 159 SCT patients 10 v 20 threshold for prophylaxis 2 groups matched patient and SCT characteristics Major bleeding 14% v 17% CNS bleeds 2 v 1 Bleeding deaths - none Bleeding days in both Platelet transfusions v 10.2 No significant differences Stanworth et al, Cochrane Database Syst Rev, 2004 Biol Blood Marrow Transplant 2002,8, Mechanisms of Alloantibody formation Leucocyte Depleted Blood Components DC in transfused blood components interact with recipient T cells Leads to HLA antibody formation DC removal by filtration or inactivation using UVB irradiation minimizes alloimmunisation Reduce HLA - alloimmunisation and platelet transfusion refractoriness Lessen graft rejection in SAA patients Reduce occurrence of FNHTR Minimize CMV transmission Do not prevent TA-GVHD - however only 2 SHOT reports since LD 3
4 Are Leucocyte Depleted Components still indicated in Aplastic Anaemia (AA)? Trial to Reduce Alloimmunisation to Platelets (TRAP) Study Historically transfusion associated with higher rates of graft rejection in AA patients (mha sensitisation) Impact of LD in the modern era where buffy coat transfusions rarely given and supportive care delivered to a higher standard? Study of 24 transfused AA patients: 16 no HLA antibodies 8 had HLA T6379 Txs given to 533 patients Response better: splenectomy, increasing age Response worse: 2+ pregnancies, Male, splenomegaly, bleeding, fever Infection, DIC, presence of HLA antibodies, more transfusions, heparin, amphotericin 2/16 formed HLA antibodies at 9(1-15) months but not refractory 3/8 HLA antibodies disappeared using HLA matched LD components; controls 50% HLA antibody + Suggests that patients with AA should receive LD components from diagnosis Killick et al, Br J Haematol, 1997 TRAP Study Group, NEJM,1997,337, TRAP Study Cytomegalovirus (CMV) Highly cell associated; persists in latent state Transmitted by transfusion Seroprevalence: varies 50-98% HLA antibody+ excluded Causes severe infections in BMT patients Slichter s et al, Blood,2005,105, Transmission can be minimized by serological testing or LD 4
5 CMV Infection Risk of transfusing CMV unscreened blood components (BC) to -/- transplants is 32-37% CMV negative products have minimal impact if donor positive Present in CD34+ and CD33+ cells; productive infection via monocytemacrophage lineage Problems interpreting existing studies relate to era, type of process e.g. LD, patient group not all SCT, CMV infection v CMV disease CMV Intervention Studies in SCT patients CMV negative or No. of CMV CMV Ref. LD patients infection disease 1. CMV- 252* 4(1.4%) 0 Bowden 1995 LD 250* 6(2.4%) 6(2.4%) Bowden BOTH 33 3% 0 Ljungman 2004 LD 49 6% 0 Ljungman (a) CMV -/LD CMV (1.7%) 0 Nichols 2003 (b) CMV -/LD CMV+/aph PC (4%) 1 Nichols CMV (0.9%) 0 Foot 1998 Total (1.5%) 7(0.46%) * secondary end point 5
6 THE BOWDEN STUDY The Nichols Study CMV-related deaths only in LD group Patients pre-transplant serostatus not always clear Transfusions not leucocyte depleted prior to storage Bedside LD doesn t work for alloimmunisation* *HLA antibodies in 37.5% NF v 22% F (p=0.07) FNHTRs in 37% NF v 34% F (p=0.71) Blood product support per patient during the first 100 days after transplantation in period 1 and period 2 Blood product Period 1 (±SE) Period 2 (±SE) p Total units 23.7 ± ± Total red blood cell 10.5 ± ± (RBC) units Filtered RBC units from CMV + donor 0.08 ± ± Total platelets (PLT) 13.2 ± ± Filtered pooled PLT donor 0.16 ± ± from CMV + LR apheresis PLT from CMV + donor ± 0.2 (8.2%) <.001 Total filtered products from CMV + donor 0.24 ± 0.05 (1%) 0.41 ± 0.06 (9.88).03 CMV indicates cytomegalovirus; SE, standard error; LR, leukoreduced. * Period 1: April 1994-November 1996, N = 360 patients. Period 2: December 1996-February 2000, N = 447 patients. Table reports units of product (ie, one unit from one donor). For pooled platelets, one "unit" represents pool of 6 random concentrate CMV status of pool is positive if one unit in pool is positive or unknown. RECOMMENDATION - either approach is acceptable *Williamson et al, 1998, Blood Nichols et al, 2003 Nichols et al, 2003 Not a PRCT Probabilities of CMV infection very low 1.7% v 4.0% (p=0.05) Only 1 patient developed CMV disease with monitoring and use of ganciclovir Authors conclude that their report should spur further investigation 6
7 Review and Meta-analysis of CMV negative and LD blood components TA - GVHD 1/3 studies showed benefit for CMV negative v LD components META-ANALYSIS: risk reduction (RR) v control for CMV negative= 93.1%; RR for LD = 92.3% Caused by transfused alloreactive lymphocytes Invariably fatal: 13/13 SHOT reports over 8 years CMV negative v LD gave RR for CMV negative of 58% suggesting that these are more efficacious in preventing acquired CMV infection Problems era, not all SCT patients, methodological issues Vamvakas, Transfus Med Rev, 2005 Prevented by 2500cGy gammairradiation, X-irradiation Also likely to be prevented by photochemical treatment Strategies for Prevention of TA- GVHD Blood Component Irradiation: BCSH Guidelines Gamma-irradiation (min 2500 cgy)is the standard of care Allogeneic HSC recipients from conditioning for 6 months or until L = 1 x 10 9 /L and no a/c GVHD Allogeneic HSC donors but little autologous blood X irradiation shown to be equally effective in leucocyte inactivation and component quality(raycell RS3000 used in Euroipe and US) Autologous HSC recipients for 3 months (6 months if TBI) All donations from HLA matched donors or 1st/2nd degree relatives All granulocyte transfusions Leucodepletion undoubtedly reduces but not totally protective? All patients with Hodgkins disease (not NHL) Patients treated with purine analogues, e.g. fludarabine Patients with congenital immunodeficiency status BCSH Updated Guideline (Draft),
8 TA-GvHD since the introduction of LD Granulocyte Transfusions Key Questions 13 cases of TA-GVHD reported to SHOT 11 non-ld; 2 LD Which products are available? No cases since non-irradiated transfusions to high risk recipients Prophylactic and/or therapeutic use? Included BMT, HD and fludarabine therapy (diagnoses in 62%) and no proven cases of GVHD SHOT data may be an underestimate Shapira et al, BMT, 2005 What are the toxicities? Is there data available to guide decision making? Williamson et al, Transfusion, 2007 Granulocyte Transfusions (GTX) Systematic Reviews of Granulocyte Transfusions (GTX) Pooled buffy coats optimised granulocyte component (OGC) Yield: non-mobilised <1 x mobilised usually >4 x Cochrane review of RCTs comparing GTX v control* 10 trials met criteria; 9/10 random allocation Non-mobilised apheresis granulocytes G-CSF mobilised granulocytes Consider fitness to donate, venous access, ABO, CMV, WBC compatibility Mobilisation steroids - G-CSF Adverse effects on the donor: - G-CSF-related e.g. bone pain - steroid-related e.g. insomnia - apheresis-related e.g. venepuncture All conducted >20 years ago except for 1 where G-CSF was used Relative risk (RR) of mortality 0.94 Excluding 2 studies with doses <1 x RR for mortality and mortality due to infection were 0.69 and 0.36 Suggests that prophylactic GTX may reduce mortality Cochrane Review of GTX as therapy in 8 trials including 310 patients evidence inconclusive due to heterogeneity in studies** Times change antibiotics, better supportive care *Massey et al. Cochrane Database Syst Rev, 2009; **Stanworth et al Cochrane Database Syst Rev,
9 Prophylaxis: Episodes of infection Prophylaxis: Mortality due to infection Therapy: Subgroup analysis of mortality: by dose Granulocyte Transfusions as Prophylaxis 22/16 allograft patients with proven/possible fungal infection Median 4 GTX with mean dose of 5.95 x Mean granulocyte increment 1.5 x 10 9 /L Significant reduction in - neutropenia - incidence/duration of fever - maximal CRP Some patients showed improved pulmonary infiltrates Stanworth et al 2005 Cochrane data base. FURTHER STUDIES ARE NEEDED Kerr et al, Br J Haematol, 2003; Robinson and Marks, BMT,
10 Granulocyte Transfusions as Therapy Transfusion in Sickle Cell Patients who undergo SCT Daily/ twice daily using family, friends and community-based donors 6 studies using G-CSF-mobilised GTX for neutropenic sepsis Most were small, single-centre studies with diverse haematological diagnoses, infections, lack of controls Largest, controlled study showed non-significant trend to worse outcome with GTX (Hubel et al, Transfusion, 2002) Remainder showed improvement Impact of GTX on clinical outcome currently unclear Unique transfusion characteristics including prophylaxis against stroke 27 SCD patients had MSD SCT using myeloablative conditioning between Extended red cell phenotypic matching in 6 alloimmunised patients [C, c, E, e, K, Fy(a), Jk(b)] Limited matching in 14 non-sensitised patients [ C, c, E, e, K] No phenotypic matching in 7 Tx requirements: Red cells 7(3-15); platelets 13.5(4-48) Increased red cell Tx in patients with SCT-related morbidity e.g. VOD Increased phenotypic matching reduced red cell transfusions Robinson and Marks, BMT, 2004 McPherson et al, Transfusion, 2009 Types of ABO incompatible BMT Problems in ABO Incompatible SCT Classified according to whether donor isohaemagglutinins, antigens or both are incompatible with the recipient Major patient has antibodies directed against donor RBC antigens e.g. A donor O recipient Failure of engraftment no Acute HTR when graft given - remove donor RBC or plasma Delayed erythropoiesis e.g. anti-a in recipient Minor donor has antibodies directed against recipient RBC antigens e.g. O donor A recipient Bidirectional e.g. A donor B recipient Delayed haemolysis - passenger lymphocyte syndrome; max d9-16 GITMO survey showed high heterogeneity of practice in testing, methods for dealing with ABO incompatible grafts and post-sct support* *Raimondi R et al, BMT,
11 Haemolysis in ABO Incompatible BMT Management of Graft in ABO Mismatched BMT The immediate risk of major ABO mismatch is haemolysis - high for bone marrow since volume of RBC is high (25-35% of component volume) - low for peripheral blood stem cells (PBSC) since volume of RBC is low (2-5% of component volume) Risk reduced by RBC removal from the graft Depends on isoagglutinin titre Risk of minor ABO mismatch is delayed haemolysis Major depends on graft volume and recipient anti-a,b titres If titres less than 1:32 infuse unmodified Small amounts of mismatched RBC are removed rapidly after infusion causing the titre to fall Higher titres remove red cells by sedimentation or using cell separators - deplete isoagglutinins in recipient by immunoabsorption or plasma exchange (where cell dose critical) Minor deplete plasma from the graft by centrifugation according to volume/titre Management of the Patient in ABO Incompatible BMT Management in ABO Incompatible BMT Pre-transplant blood group, antibody screen and isoagglutinin titres Patient must be well hydrated and carefully observed Watch for signs of immediate and delayed haemolysis Rowley SD, Bone Marrow Transplantation,
12 ABH Isoagglutinin Persistence after BMT Pure Red Cell Aplasia after BMT Slower in ABO mismatched v compatible BMT Slower if Reduced Intensity Conditioning (RIC) used Risk Factors include (i) the use of cyclosporin A (CSA) to prevent GvHD (ii) High initial or persistently elevated recipient anti-donor isohaemagglutinin titre (iii) RBC incompatibilty involving the A antigen Recipient haemopoiesis erradicated by conditioning and inhibition of donor red cells by persisting anti-donor isohaemagglutinin Rowley SD, Bone Marrow Transplantation, 2001 Glycophorin stain Reduced Intensity Conditioning (RIC) delayed donor red cell chimerism Delayed Donor Red Cell Chimerism - PRCA Comparison of RIC v MAT BMT where major ABO mismatch RIC MAT Total BMT ABO MM Evaluable PRCA occurred in 4 RIC patients These patients showed rapid donor chimerism in T cell and myeloid cells (mean 14 and 30 days) RIC fludarabine + cyclophosphamide MAT TBI + cyclophosphamide Outcome donor red cell chimerism delayed in RIC - delay correlated with host anti-donor isoagglutinin titres - titres decreased more slowly in RIC - PRCA in 4/14 RIC v 0/12 MAT Anti-donor isoagglutinins >1+ : 166 days ( ) Red cell chimerism delayed for 181 days ( ) PRCA resolved with CSA discontinuation 3/4 + PEX in1/4 Patients failed to respond to EPO Bolan et al, Blood, 2001 Bolan et al, Blood,
13 RIC v MAT: Red Cell Usage Passenger Lymphocyte Syndrome (PLS) Haemolysis of patients red cells after BMT by graft produced isoagglutinins Passenger B lymphocytes in the graft are restimulated by host AB delayed and sometimes massive haemolysis May be fatal; occurs maximally d 9-16 Rarely seen where BM grafts T cell depleted with alemtuzumab (anti B cell effect) Mijovic et al, Br J Haematol, 2008 Post graft methotraxate and mycophenelate mofetil (MMF) may reduce RIC More Haemolysis in ABO minor mismatched BMT? Effects of ABO Incompatibility on BMT Outcome RIC associated with reduced overall red cell and platelet transfusion requirements ABO mismatched RIC associated with higher transfusion requirements, more haemolysis and cases of PRCA (as in myeloablative SCT) Worel et al* suggested that PLS might be worse in the setting of RIC 32 patients RIC allogeneic PBSCT; 10/30 had minor mismatch; 5/10 had severe haemolysis and 3 died Introduced prophylactic red cell exchange in next 20 patients 1/20 showed signs of mild haemolysis *Worel et al,transfusion, 2007 Red cell antigens are not major histocompatibility antigens Most reports show no difference in overall survival (OS), treatment-related mortality(trm), graft rejection or GvHD e.g. Seebach et al 3103 patients: 2108 identical minor major bidirectional JMDP ABO mismatch reduced OS, increased TRM, delayed trilineage engraftment and increase severe GvHD (Kimura F, Haematologica, 2008) 13
14 ABO Incompatible SCT - Blood Groups to Transfuse Outcome after ABO mismatched BMT Seebach et al, Biol Blood Marrow Transplant, 2005 Need to consider donor and patient ABO groups Depends on whether red cells, platelets or FFP Check for disappearance of antidonor ABO antibodies, the antiglobulin test and disappearance of recipient type red cells ABO Incompatible SCT Transfusion Support Summary and Future Directions SCT patients are highly immunocompromised Susceptible to all complications of transfusion Particular challenges include changing blood groups, prevention and management of infection, need for irradiated blood components Clear policies for transfusion and regular audit of outcome are essential 14
15 Thank You 15
EBMT2008_1_21:EBMT :11 Pagina 146 * CHAPTER 7. Transfusion policy. D.H. Pamphilon
EBMT2008_1_21:EBMT2008 6-11-2008 9:11 Pagina 146 * CHAPTER 7 Transfusion policy D.H. Pamphilon EBMT2008_1_21:EBMT2008 6-11-2008 9:11 Pagina 147 CHAPTER 7 Transfusion policy 1. Introduction Haematopoietic
More informationAll you wanted to know about transfusion support for transplants
All you wanted to know about transfusion support for transplants Dr Dora Foukaneli NHSBT and Addenbrooke s Hospital Cambridge When / why / why not? What ABO group? Do other groups matter? Transplantation
More informationCarol Cantwell Blood Transfusion Laboratory Manager St Mary s Hospital, ICHNT
Carol Cantwell Blood Transfusion Laboratory Manager St Mary s Hospital, ICHNT History Why is blood transfusion involved? What tests are performed in blood transfusion and why? What does a protocol look
More informationTransplants. Mickey B. C. Koh
Transfusion in Stem Cell Transplants Mickey B. C. Koh Director: Stem Cell Transplant Programme Department of Haematology, St. George s Hospital and Medical School, London, UK Medical Director: Cell Therapy
More informationGuidelines for the Management of Platelet Transfusion Refractoriness GUIDELINES FOR THE MANAGEMENT OF PLATELET TRANSFUSION REFRACTORINESS
GUIDELINES FOR THE MANAGEMENT OF PLATELET TRANSFUSION REFRACTORINESS Reviewed by Dr Colin Brown (26/03/2008) Author(s): Colin Brown Page 1 of 7 Purposes To define and recommend policies and procedures
More informationABO INCOMPATILIBITY AND TRANSPLANTATION
ABO INCOMPATILIBITY AND TRANSPLANTATION Aleksandar Mijovic Consultant Haematologist/Senior Lecturer King s College Hospital/NHS Blood and Transplant London, UK RTC Edu Meeting May 2017 ABO antigens Expressed
More informationSpecific Requirements
Specific Requirements AIMS Specific requirements your patients have for transfusion and how this is managed Classify which patients require: Irradiated components CMV negative components Washed components
More informationBlood Components & Indications for Transfusion. Neda Kalhor
Blood Components & Indications for Transfusion Neda Kalhor Blood products Cellular Components: Red blood cells - Leukocyte-reduced RBCs - Washed RBCs - Irradiated RBCs Platelets - Random-donor platelets
More informationOne Day BMT Course by Thai Society of Hematology. Management of Graft Failure and Relapsed Diseases
One Day BMT Course by Thai Society of Hematology Management of Graft Failure and Relapsed Diseases Piya Rujkijyanont, MD Division of Hematology-Oncology Department of Pediatrics Phramongkutklao Hospital
More information5/9/2018. Bone marrow failure diseases (aplastic anemia) can be cured by providing a source of new marrow
5/9/2018 or Stem Cell Harvest Where we are now, and What s Coming AA MDS International Foundation Indianapolis IN Luke Akard MD May 19, 2018 Infusion Transplant Conditioning Treatment 2-7 days STEM CELL
More informationBlood transfusion. Dr. J. Potgieter Dept. of Haematology NHLS - TAD
Blood transfusion Dr. J. Potgieter Dept. of Haematology NHLS - TAD General Blood is collected from volunteer donors >90% is separated into individual components and plasma Donors should be: healthy, have
More informationManagement of platelet refractory patients, why does your patient keep on bleeding? Dr Colin Brown, H&I Dept, NHSBT Colindale
Management of platelet refractory patients, why does your patient keep on bleeding? Dr Colin Brown, H&I Dept, NHSBT Colindale Pooled Platelets (Buffy Coat Derived) Adult dose from 4 ABO-identical donors
More information25/10/2017. Clinical Relevance of the HLA System in Blood Transfusion. Outline of talk. Major Histocompatibility Complex
Clinical Relevance of the HLA System in Blood Transfusion Dr Colin J Brown PhD FRCPath. October 2017 Outline of talk HLA genes, structure and function HLA and immune complications of transfusion TA-GVHD
More informationBLOOD TRANSFUSION. Dr Lumka Ntabeni
BLOOD TRANSFUSION Dr Lumka Ntabeni Blood transfusion definition SAFE transfer of BLOOD COMPONENTS from a DONOR to a RECEPIENT CONTENT Brief history of blood transfusion How is safety guaranteed? How do
More informationApheresis: Transfusion Indications. Sasha Wilson: Transfusion Senior Nurse
Apheresis: Transfusion Indications Sasha Wilson: Transfusion Senior Nurse Apheresis: Transfusion Indications Focus of talk will be blood component transfusion in the context of apheresis procedures: Special
More informationRBC Transfusion
RBC Transfusion 2014년혈액종양내과춘계연수강좌 Won SikLee, M.D., Ph.D. Division of Hemato-Oncology, Department of Internal Medicine, Inje University College of Medicine, Busan Paik Hospital 2014. 06. 21. Background
More informationRob Wynn RMCH & University of Manchester, UK. HCT in Children
Rob Wynn RMCH & University of Manchester, UK HCT in Children Summary Indications for HCT in children Donor selection for Paediatric HCT Using cords Achieving engraftment in HCT Conditioning Immune action
More informationThe Use of HLA /HPA Selected Platelets
The Use of HLA /HPA Selected Platelets Dr Colin Brown PhD FRCPath. Consultant Clinical Scientist Histocompatibility and Immunogenetics HLA and Transfusion Human Leucocyte Antigens HLA Human Platelet Antigens
More informationTransfusion: indications (RBC, platelets, granulocytes, plasma)
Transfusion: indications (RBC, platelets, granulocytes, plasma) BHS Educational Course: course n 5 22/3/2014 Timothy Devos (KU Leuven) Indications for the transfusion of erythrocytes General rules only
More informationDefinitions of Current SHOT Categories & What to Report
Definitions of Current SHOT Categories & What to Report Revised March 2011 1 ADVERSE EVENTS TERM DEFINITION WHAT TO REPORT IBCT - Wrong Blood Transfused (Incorrect Blood Component Transfused) Where a patient
More informationSource of platelet concentrates FACHBEREICH MEDIZIN
FACHBEREICH MEDIZIN Efficacy and safety of platelet concentrates from platelet apheresis donations or whole blood donations Gregor Bein Institute for Clinical Immunology and Transfusion Medicine Justus-Liebig-University
More informationPreventing CMV Transmission through Leukodepletion
Preventing CMV Transmission through Leukodepletion Possibility & Facts Prof.S.B.Rajadhyaksha, MD,DTM,PGDMLS Head, Dept. of Transfusion Medicine Tata Memorial Hospital, Mumbai 1 Donor Leukocytes Linked
More informationBlood Transfusion. What is blood transfusion? What are blood banks? When is a blood transfusion needed? Who can donate blood?
What is blood transfusion? A blood transfusion is a safe, common procedure in which blood is given through an intravenous (IV) line in one of the blood vessels. A blood transfusion usually takes two to
More informationAll institutions that transfuse blood components and products should implement national and local policies and written procedures for:
5.0 GENERAL GUIDE TO GOOD TRANSFUSION PRACTICE Blood and the various components prepared or manufactured from it are biologic (in the case of blood cells, living human tissues) products intended for use
More informationSupporting solid organ transplants: Challenges for Blood Transfusion Labs
Supporting solid organ transplants: Challenges for Blood Transfusion Labs Dora Foukaneli Consultant in Haematology and Transfusion Medicine NHSBT Cambridge and Addenbrooke s Hospital Addenbrooke s Blood
More informationChapter 13 ADVERSE TRANSFUSION EVENTS
Chapter 13 ADVERSE TRANSFUSION EVENTS PRACTICE POINTS The most common severe reaction is ABO incompatibility caused by mis-identification or mis-labelling of the blood component, patient or pre-transfusion
More informationClinical Relevance of the HLA System in Blood Transfusion. Dr Colin J Brown PhD FRCPath. October 2017
Clinical Relevance of the HLA System in Blood Transfusion Dr Colin J Brown PhD FRCPath. October 2017 Outline of talk HLA genes, structure and function HLA and immune complications of transfusion TA-GVHD
More informationTransfusion challenges in transplantation fields
Transfusion challenges in transplantation fields Unité d hématologie transfusionnelle Département des Spécialités de Médecine Dr. S. Waldvogel Abramowski Swisstransfusion 2018 Friday 24 th August 2018
More informationAn Approach to the Patient Refractory to Platelets Transfusion. Harold Alvarez, MD
Harold Alvarez, MD Objectives Explain the etiology of platelet refractoriness Discuss the different types of platelet refractoriness Describe how platelet refractoriness is diagnosed Discuss different
More informationWhat s a Transplant? What s not?
What s a Transplant? What s not? How to report the difference? Daniel Weisdorf MD University of Minnesota Anti-cancer effects of BMT or PBSCT [HSCT] Kill the cancer Save the patient Restore immunocompetence
More informationGuidelines for Gamma Irradiation of Blood Components
AUSTRALIAN & NEW ZEALAND SOCIETY OF BLOOD TRANSFUSION INC. AUSTRALIAN RED CROSS BLOOD SERVICE NEW ZEALAND BLOOD SERVICE Guidelines for Gamma Irradiation of Blood Components Revised 2003 AN ZS B T Australian
More informationHematopoietic Stem Cells, Stem Cell Processing, and Transplantation
Hematopoietic Stem Cells, Stem Cell Processing, and Joseph (Yossi) Schwartz, M irector, Hemotherapy and Stem Cell Processing Facility Bone Marrow Can Cure: Leukemia Lymphoma Multiple Myeloma Genetic iseases:
More informationThe role of HLA in Allogeneic Hematopoietic Stem Cell Transplantation and Platelet Refractoriness.
The role of HLA in Allogeneic Hematopoietic Stem Cell Transplantation and Platelet Refractoriness. Robert Liwski, MD, PhD, FRCPC Medical Director HLA Typing Laboratory Department of Pathology Dalhousie
More informationBlood Product Modifications: Leukofiltration, Irradiation and Washing
1. Leukocyte Reduction Definitions and Standards: o Process also known as leukoreduction, or leukofiltration o Applicable AABB Standards, 25th ed. Leukocyte-reduced RBCs At least 85% of original RBCs
More informationHematopoietic Stem Cell Transplant in Sickle Cell Disease- An update
Hematopoietic Stem Cell Transplant in Sickle Cell Disease- An update Dr Chirag A Shah Diplomate American Board of Hematology and Medical Oncology Director, Dept of Hemato-Oncology and Stem Cell Transplant
More informationAcute Transfusion Reactions (Allergic, Hypotensive and Severe Febrile) (ATR) n=296 11
REACTIONS IN PATIENTS: Serious adverse reactions including EU definition ANNUAL SHOT REPORT 2015 Acute Transfusion Reactions (Allergic, Hypotensive and Severe Febrile) (ATR) n=296 11 Authors: Janet Birchall,
More informationHLA Selected Platelets
HLA Selected Platelets Dr PhD Clinical Scientist Department of Histocompatibility & Immunogenetics NHS Blood and Transplant Colindale Poor increment (
More informationBlood is serious business
Transfusion at RCH BLOOD TRANSFUSION Anthea Greenway Dept of Clinical Haematology >10000 fresh blood products per year Supports craniofacial and cardiac surgery Support bone marrow, liver transplant and
More informationCrossmatching and Issuing Blood Components; Indications and Effects.
Crossmatching and Issuing Blood Components; Indications and Effects. Alison Muir Blood Transfusion, Blood Sciences, Newcastle Trust Topics Covered Taking the blood sample ABO Group Antibody Screening Compatibility
More informationTransfusion-Associated Graft-versus-Host Disease TRANSFUSION-ASSOCIATED GRAFT-VERSUS-HOST DISEASE
TRANSFUSION-ASSOCIATED GRAFT-VERSUS-HOST DISEASE D H Pamphilon for the NBS Transfusion Medicine Clinical Policies Group. Membership: M F Murphy (Chair), A Copplestone, M Gesinde, S MacLennan, C Morgan,
More informationSickle Cell Diseasechronic. curable disease? Objectives. Why would a family ask about cure for SCD?
Sickle Cell Diseasechronic illness or curable disease? Gregory M.T. Guilcher MD, FRCPC, FAAP Objectives To review the general principles of hematopoietic stem cell transplantation (HSCT), including risks
More informationUKGS TRANSFUSION SERVICE PRODUCTS AND AVAILABILITY
Lexington, KY Page 1 of 13 Affected Sites: Enterprise Chandler X Good Samaritan I. PRINCIPLE: The UK Good Samaritan Hospital is dedicated to serve the patients with safe, high quality blood products and
More informationWhat the Transfusion Scientist should know about Stem Cells. Dr Claire Wiggins BBTS September 2017
What the Transfusion Scientist should know about Stem Cells Dr Claire Wiggins BBTS September 2017 What is a stem cell? Undifferentiated cell Can divide and self renew for long periods Differentiate into
More informationBMTCN REVIEW COURSE PRE-TRANSPLANT CARE
BMTCN REVIEW COURSE PRE-TRANSPLANT CARE Jennifer Shamai MS, RN, AOCNS, BMTCN Professional Practice Leader Department of Clinical Practice And Professional Education Click How to edit the Master Experts
More informationStem cell transplantation. Dr Mohammed Karodia NHLS & UP
Stem cell transplantation Dr Mohammed Karodia NHLS & UP The use of haemopoeitic stem cells from a donor harvested from peripheral blood or bone marrow, to repopulate recipient bone marrow. Allogeneic From
More informationPUO in the Immunocompromised Host: CMV and beyond
PUO in the Immunocompromised Host: CMV and beyond PUO in the immunocompromised host: role of viral infections Nature of host defect T cell defects Underlying disease Treatment Nature of clinical presentation
More informationAn Introduction to Bone Marrow Transplant
Introduction to Blood Cancers An Introduction to Bone Marrow Transplant Rushang Patel, MD, PhD, FACP Florida Hospital Medical Group S My RBC Plt Gran Polycythemia Vera Essential Thrombocythemia AML, CML,
More informationBlood Transfusion Guidelines in Clinical Practice
Blood Transfusion Guidelines in Clinical Practice Salwa Hindawi Director of Blood Transfusion Services Associate Professor in Haematology and Transfusion Medicine King Abdalaziz University, Jeddah Saudi
More informationTrends in Hematopoietic Cell Transplantation. AAMAC Patient Education Day Oct 2014
Trends in Hematopoietic Cell Transplantation AAMAC Patient Education Day Oct 2014 Objectives Review the principles behind allogeneic stem cell transplantation Outline the process of transplant, some of
More informationCTYOMEGALOVIRUS (CMV) - BACKGROUND
CTYOMEGALOVIRUS (CMV) - BACKGROUND PURPOSE The flowing information provides guidance on the use of CMV negative blood components provided by the blood bank at the Royal Children s Hospital (RCH) including
More informationAllogeneic Hematopoietic Stem Cell Transplantation: State of the Art in 2018 RICHARD W. CHILDS M.D. BETHESDA MD
Allogeneic Hematopoietic Stem Cell Transplantation: State of the Art in 2018 RICHARD W. CHILDS M.D. BETHESDA MD Overview: Update on allogeneic transplantation for malignant and nonmalignant diseases: state
More informationMUD HSCT as first line Treatment in Idiopathic SAA. Dr Sujith Samarasinghe Great Ormond Street Hospital for Children, London, UK
MUD HSCT as first line Treatment in Idiopathic SAA Dr Sujith Samarasinghe Great Ormond Street Hospital for Children, London, UK No Financial Disclosures Guidelines for management of aplastic anaemia British
More informationCase-Control Study: ABO-Incompatible Plasma Causing Hepatic Veno-Occlusive Disease in HSCT
Case-Control Study: ABO-Incompatible Plasma Causing Hepatic Veno-Occlusive Disease in HSCT Erin Meyer, DO, MPH Assistant Medical Director of Blood, Tissue, and Apheresis Services Children s Healthcare
More informationNew Evidence reports on presentations given at EHA/ICML Bendamustine in the Treatment of Lymphoproliferative Disorders
New Evidence reports on presentations given at EHA/ICML 2011 Bendamustine in the Treatment of Lymphoproliferative Disorders Report on EHA/ICML 2011 presentations Efficacy and safety of bendamustine plus
More informationCAUTION: Refer to the Document Library for the most recent version of this document. Platelet Transfusion Guideline for practice
Platelet Transfusion Guideline for practice Directorate SharePoint Index Directory Year Version Number Central Index Number Endorsing Committee Date Endorsed Approval Committee Date Approved Author Name
More informationCONSIDERATIONS IN DESIGNING ACUTE GVHD PREVENTION TRIALS: Patient Selection, Concomitant Treatments, Selecting and Assessing Endpoints
CONSIDERATIONS IN DESIGNING ACUTE GVHD PREVENTION TRIALS: Patient Selection, Concomitant Treatments, Selecting and Assessing Endpoints CENTER FOR INTERNATIONAL BLOOD AND MARROW TRANSPLANT RESEARCH Potential
More informationHematopoietic Stem Cells
Hematopoietic Stem Cells, Stem Cell Processing, and Joseph (Yossi) Schwartz, M irector, Hemotherapy and Stem Cell Processing Facility E-mail: js2745@columbia.edu Hematopoietic Stem Cells Sustain hematopoiesis
More informationReduced-intensity Conditioning Transplantation
Reduced-intensity Conditioning Transplantation Current Role and Future Prospect He Huang M.D., Ph.D. Bone Marrow Transplantation Center The First Affiliated Hospital Zhejiang University School of Medicine,
More informationShall young patients with severe aplastic anemia without donors receive BMT from alternative source of HCT? Elias Hallack Atta, MD, PhD
Shall young patients with severe aplastic anemia without donors receive BMT from alternative source of HCT? Elias Hallack Atta, MD, PhD Declaração de Conflito de Interesse Declaro que possuo conflito de
More informationTransfusion support for the oncology patient
PART III Oncology CHAPTER 50 Transfusion support for the oncology patient Wade L. Schulz & Edward L. Snyder Department of Laboratory Medicine, Yale School of Medicine, Yale University; and Blood Bank,
More informationProvision of Red Cell Transfusion Support for Transfusion Dependent Patients
1.0 Definition Transfusion dependent patients are those who require frequent and long-term transfusion support to sustain life. Most such patients have been diagnosed with one of the following conditions:
More informationStem Cell Transplantation for Severe Aplastic Anemia
Number of Transplants 10/24/2011 Stem Cell Transplantation for Severe Aplastic Anemia Claudio Anasetti, MD Professor of Oncology and Medicine Chair, Blood and Marrow Transplant Dpt Moffitt Cancer Center
More informationHLA-DR-matched Parental Donors for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with High-risk Acute Leukemia
BRIEF COMMUNICATION HLA-DR-matched Parental Donors for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with High-risk Acute Leukemia Shang-Ju Wu, Ming Yao,* Jih-Luh Tang, Bo-Sheng Ko, Hwei-Fang
More informationOverview of Aplastic Anemia. Overview of Aplastic Anemia. Epidemiology of aplastic anemia. Normal hematopoiesis 10/6/2017
Overview of Aplastic Anemia Overview of Aplastic Anemia Peter Westervelt, MD, PhD Professor of Medicine Chief, BMT/Leukemia Section Washington University School of Medicine Epidemiology Normal hematopoiesis
More informationHaploidentical Transplantation: The Answer to our Donor Problems? Mary M. Horowitz, MD, MS CIBMTR, Medical College of Wisconsin January 2017
Haploidentical Transplantation: The Answer to our Donor Problems? Mary M. Horowitz, MD, MS CIBMTR, Medical College of Wisconsin January 2017 Allogeneic Transplant Recipients in the US, by Donor Type 9000
More informationTransplantation - Challenges for the future. Dr Gordon Cook S t James s Institute of Oncology, Leeds Teaching Hospitals Trust
Transplantation - Challenges for the future Dr Gordon Cook S t James s Institute of Oncology, Leeds Teaching Hospitals Trust Bone Marrow Transplantation Timeline, 1957-2006 Appelbaum F. N Engl J Med 2007;357:1472-1475
More informationRevised November 2012
Revised November 2012 1 ADVERSE EVENTS IBCT - Wrong Blood Transfused (Incorrect Blood Component Transfused) IBCT- SRNM (Specific Requirements Not Met) Where a patient was transfused with a blood component
More informationT-CELL DEPLETION: ALEMTUZUMAB IN THE BAG
UCT T-CELL DEPLETION: ALEMTUZUMAB IN THE BAG Nicolas Novitzky PhD, FCP(SA) Engraftment variables in Allo SCT Host HLA identity Integrity of marrow stroma Disease type and status Previous chemotherapy Graft
More informationNeutrophil Recovery: The. Posttransplant Recovery. Bus11_1.ppt
Neutrophil Recovery: The First Step in Posttransplant Recovery No conflicts of interest to disclose Bus11_1.ppt Blood is Made in the Bone Marrow Blood Stem Cell Pre-B White cells B Lymphocyte T Lymphocyte
More informationStem cell transplantation for haemoglobinopathies. Dr P J Darbyshire Birmingham Childrens Hospital
Stem cell transplantation for haemoglobinopathies Dr P J Darbyshire Birmingham Childrens Hospital Survival by Cohort of Birth (N=977) 1.00 85-97 80-84 75-79 70-74 0.75 Survival Probability 0.50 0.25 P
More informationGranulocyte Transfusions: A Clinician s Perspective Is there a role for this therapy?
Granulocyte Transfusions: A Clinician s Perspective Is there a role for this therapy? Doug Myers, MD Associate Professor of Pediatrics Children s Mercy Hospital, Kansas City Objectives Understand the rationale
More informationMary Berg, M.D. Medical Director, Transfusion Services Associate Professor of Pathology University of Colorado Hospital
Transfusion Reactions/Complications Mary Berg, M.D. Medical Director, Transfusion Services Associate Professor of Pathology University of Colorado Hospital Acute Transfusion Reactions Can be seen with
More informationTransfusion-associated graft-versus-host disease
CHAPTER 6 Transfusion-associated graft-versus-host disease Eric A. Gehrie, 1 Edward L. Snyder, 1 & Alex B. Ryder 2 1 Department of Laboratory Medicine, Yale School of Medicine, Yale University; and Blood
More informationObjectives. What is Aplastic Anemia. SAA 101: An Introductory Course to Severe Aplastic Anemia
SAA 101: An Introductory Course to Severe Aplastic Anemia David A. Margolis, MD Professor of Pediatrics/Medical College of Wisconsin Program Director/ Children s Hospital of Wisconsin BMT Program Objectives
More informationJohn Goodwin. H&I Laboratory, National Blood Service, Sheffield. FIMLS, MPhil, DipRCPath. John Goodwin, H&I Department, Sheffield
John Goodwin FIMLS, MPhil, DipRCPath H&I Laboratory, National Blood Service, Sheffield Patient categories Definitions and background Algorithm Logistics Statistics Troubleshooting / questions Patients
More informationTRANSFUSION REACTIONS
14 TRANSFUSION REACTIONS 14.1 INTRODUCTION Transfusion of blood and blood products are reported to cause reactions during or after procedure specially in patients who receive multiple transfusions. These
More informationTransfusion Reactions. Directed by M-azad March 2012
Transfusion Reactions Directed by M-azad March 2012 Transfusion Reactions are Adverse reactions associated with the transfusion of blood and its components Transfusion reactions Non-threatening to fatal
More informationUNRELATED DONOR TRANSPLANTATION FOR SICKLE CELL DISEASE AN UPDATE
UNRELATED DONOR TRANSPLANTATION FOR SICKLE CELL DISEASE AN UPDATE Naynesh Kamani, M.D. Children s National Medical Center GW University School of Medicine Washington, DC SCD scope of problem in USA Commonest
More informationReporting from Council of Europe member states on the collection, testing and use of blood and blood components in Europe The 2006 Survey
Reporting from Council of Europe member states on the collection, testing and use of blood and blood components in Europe The 2006 Survey This questionnaire consists of three sections: A. Collection and
More informationCorporate Medical Policy
Corporate Medical Policy Hematopoietic Stem-Cell Transplantation for Waldenstrom Macroglobulinemia File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem_cell_transplantation_for_waldenstrom_macroglobulinemia
More informationDonatore HLA identico di anni o MUD giovane?
Donatore HLA identico di 60-70 anni o MUD giovane? Stella Santarone Dipartimento di Ematologia, Medicina Trasfusionale e Biotecnologie Pescara AGENDA 1. Stem Cell Donation: fatalities and severe events
More informationTransfusion Therapy & Safety. Mary Grabowski, RN, BSN, BSIA Transfusion Safety Officer PSONEC Fundamentals September, 2015
Transfusion Therapy & Safety Mary Grabowski, RN, BSN, BSIA Transfusion Safety Officer PSONEC Fundamentals September, 2015 Topics Blood Components Special Processing/Attributes Irradiation Leukoreduction
More informationUKALL14. Non-Myeloablative Conditioning Regimen (1/1) Date started (dd/mm/yyyy) (Day 7) Weight (kg) BSA (m 2 )
Non-Myeloablative Conditioning Regimen (1/1) started (dd/mm/yyyy) (Day 7) BSA (m 2 ) Weight (kg) Please enter the daily dose given in the table below: Day Fludarabine (mg) Melphalan (mg) Alemtuzumab (mg)
More informationXIV. HLA AND TRANSPLANTATION MEDICINE
XIV. HLA AND TRANSPLANTATION MEDICINE A. Introduction 1. The HLA system includes a complex array of genes and their molecular products that are involved in immune regulation and cellular differentiation.
More informationAn Overview of Blood and Marrow Transplantation
An Overview of Blood and Marrow Transplantation October 24, 2009 Stephen Couban Department of Medicine Dalhousie University Objectives What are the types of blood and marrow transplantation? Who may benefit
More informationReview of Aplastic Anemia Guidelines. Seiji Kojima MD. PhD.
Review of Aplastic Anemia Guidelines Seiji Kojima MD. PhD. Department of Pediatrics Nagoya University Graduate School of Medicine Chairman of the Severe Aplastic Anemia Working Party Asia-Pacific Blood
More informationNothing to disclose. Title of the presentation - Author
Nothing to disclose Title of the presentation - Author 1 www.ebmt.org Complications after HSCT Alicia Rovó MD London 9/04/2013 Introduction Risk factors for transplant complication Type of complications
More informationGUIDELINES FOR THE TRANSFUSION OF BLOOD COMPONENTS
CHILDREN S HOSPITALS AND CLINICS OF MINNESOTA Introduction: GUIDELINES FOR THE TRANSFUSION OF BLOOD COMPONENTS These guidelines have been developed in conjunction with the hospital Transfusion Committee.
More informationA Review of Guidelines and Evidence for the Use of Irradiated Blood Products in Solid Tumor, Chemotherapy Patients. Chris Kim 11/29/12
A Review of Guidelines and Evidence for the Use of Irradiated Blood Products in Solid Tumor, Chemotherapy Patients Chris Kim 11/29/12 Background Prevention of TAGVHD Irradiation: induces DNA crosslinks,
More informationDisclosures. Investigator-initiated study funded by Astellas
Disclosures Investigator-initiated study funded by Astellas 1 Background Widespread use of preemptive therapy strategies has decreased CMV end-organ disease to 5-8% after HCT. Implications for development
More informationSpecial Requirements Lab Matters. 21 st June Barrie Ferguson
Special Requirements Lab Matters. 21 st June 2017 Barrie Ferguson Special requirements Patients requiring Methylene Blue or Solvent Detergent treated Fresh Frozen Plasma Patients requiring apheresis platelets
More informationALL Blood Transfusion samples must be hand-written in accordance with the Trust's Blood Administration Protocol
Blood Transfusion Routine Investigations ALL Blood Transfusion samples must be hand-written in accordance with the Trust's Blood Administration Protocol Full Group & Screen 2ml EDTA Can be stored at 2-8C
More informationThe question is not whether or not to deplete T-cells, but how to deplete which T-cells
The question is not whether or not to deplete T-cells, but how to deplete which T-cells CD34+ positive selection Negative Depletion of: CD3/CD19 TcRαβ/CD19 T-cell depletion: positive selection versus negative
More informationAcute Graft-versus-Host Disease (agvhd) Udomsak Bunworasate Chulalongkorn University
Acute Graft-versus-Host Disease (agvhd) Udomsak Bunworasate Chulalongkorn University Graft-versus-Host Disease (GVHD) Background GVHD is an immunologic reaction of the donor immune cells (Graft) against
More informationTransfusion in Sickle Cell Disease What the guidelines [are likely to] say. Dr Bernard Davis Whittington Hospital, London
Transfusion in Sickle Cell Disease What the guidelines [are likely to] say Dr Bernard Davis Whittington Hospital, London Background to BCSH Guideline Rationale Current guidance in disparate publications
More informationWessex Paediatric Oncology Supportive Care Guidelines: Transfusion & Coagulation.
Wessex Paediatric Oncology Supportive Care Guidelines: Transfusion & Coagulation. Scope This guideline applies to all Paediatric Oncology patients in the region. It does not apply to neonates on neonatal
More informationOlive J Sturtevant, MHP, MT(ASCP)SBB/SLS, CQA Director, Cellular Therapy Quality Assurance Dana Farber Cancer Institute
Adverse Events associated with Cell Therapy Products Olive J Sturtevant, MHP, MT(ASCP)SBB/SLS, CQA Director, Cellular Therapy Quality Assurance Dana Farber Cancer Institute 2 Objectives Review the types
More informationFor more information about how to cite these materials visit
Author(s): Robertson Davenport, M.D., 2009 License: Unless otherwise noted, this material is made available under the terms of the Creative Commons Attribution Noncommercial Share Alike 3.0 License: http://creativecommons.org/licenses/by-nc-sa/3.0/
More informationWhat s new in Blood and Marrow Transplant? Saar Gill, MD PhD Jan 22, 2016
What s new in Blood and Marrow Transplant? Saar Gill, MD PhD Jan 22, 2016 Division of Hematology-Oncology University of Pennsylvania Perelman School of Medicine 1 Who should be transplanted and how? Updates
More informationSamples Available for Recipient Only. Samples Available for Recipient and Donor
Unrelated HCT Research Sample Inventory - Summary for First Allogeneic Transplants in CRF and TED with biospecimens available through the CIBMTR Repository stratified by availability of paired samples,
More information